Nov 08, 2022 8:00am EST IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures
Oct 26, 2022 8:00am EDT IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month
Oct 19, 2022 8:00am EDT IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery
Oct 11, 2022 8:00am EDT IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil
Aug 15, 2022 4:01pm EDT IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights
Aug 09, 2022 8:00am EDT IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022
Jul 25, 2022 8:00am EDT IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
Jul 05, 2022 8:00am EDT Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations
Jul 04, 2022 2:30pm EDT Tracking News - More Details of Marketing Progress for IceSense3™ in Mainland China
